Official UK procurement notice
e-PCR Machines and Reagents
Authority: Department of Health & Social Care (Central government)
What is being bought
Published requirement descriptionNexar platforms and associated consumables to determine the presence or absence of SARS CoV-2 via End Point-PCR from saliva samples. Includes maintenance, support and training associated with the Goods.
CPV: Biochemical analysers · Biomedical equipment · Laboratory reagents
The lotProcurement structure
single lot · no lot value publishedProcedure terms & legal framework
From the official record- Procedure method
- Award procedure without prior publication of a call for competition
- Legal basis
- CELEX · 32014L0024 Public Contracts Regulations 2015 (Directive 2014/24/EU)
- Procurement category
- Goods
- Notice status
- Awarded without competition
- Procurement threshold
- Unspecified in notice
- Regulatory regime
- Standard
- Commercial structure
- Stand-alone contract (no framework)
- Competition type
- Direct award (no call for competition)
- GPA / WTO covered
- Yes (GPA)
- Recurring procurement
- Unspecified in notice
- First published
- 20 Jan 2021, 16:00 GMT
- Last source update
- 20 Jan 2021, 16:00 GMT
- FTS notice number
2021/S 000-001179- Classification (CPV)
- Delivery area
- Official registry OCID
ocds-h6vhtk-028bf1Find a Tender
- Why no open competition
The works, supplies or services can be provided only by a particular economic operator due to absence of competition for technical reasons
- Published justification
Following an earlier contract award to LGC on 23 August 2020 for an initial purchase of Nexar platforms, the machines have now successfully passed the required testing and validations.Since the August contract award, there is a requirement for further Nexar platforms (and associated consumables) to be deployed into Mega Labs that are being established to meet national COVID-19 testing targets. DHSC considers that the required deliverables can be supplied only by LGC because the competition is absent for technical reasons, no reasonable alternative or substitute exists and the absence of competition is not the result of an artificial narrowing down of the parameters of the procurement.In particular, DHSC considers that there are no other suppliers in the market who are able to offer equipment (which is only available as part of a package including associated consumables) with the potential to achieve the ultra-high levels of testing offered by LGC's Nexar instruments.DHSC has therefore proceeded with the award of the contract to LGC for the supply further Nexar machines and associated consumables using the negotiated procedure without prior publication, pursuant to Regulation 32(2)(b)(ii) of the Public Contracts Regulations 2015 for the purpose of enabling a step-change in COVID-19 testing capacity at the UK Biocentre in Milton Keynes and the upcoming Mega Labs. Within the contract there is an option for additional Nexar platforms, and optional consumables to be called-off as required by DHSC.
Commercial outcome & contract awards
Published awards, contracts and bid statistics, not a forecast| Awarded to | Value | Date | Status |
|---|---|---|---|
| LGC Genomics Limited | £117,928,510 † | — | Awarded |
Contracts
Contract 001179-2021-1 · LGC Genomics Limited
- Signed
- 22 Dec 2020
- Value
- £117,928,510
- Status
- active
Bid statistics published by the authority
| Bids | SME | VCSE | Valid bid range |
|---|---|---|---|
| 1bids | — | — | — |
Contracting authority & participating public bodies
Dispute resolution & review bodies
- The High CourtReview body
Bidders & participating suppliers
1 commercial party on the notice- LGC Genomics LtdAwarded supplier
Official documents & specifications
Official links; attachments are not copiedNo document links were published on the notice.